Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2023
- Registration Number
- NCT00539461
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Hellenthal, Germany
Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1192
- Registration Number
- NCT00539214
- Locations
- 🇩🇪
Boehringer Ingelheim, Hellenthal, Germany
Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives
- Conditions
- HypertensionObesity
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5827
- Registration Number
- NCT00539487
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 2, Übach-Palenberg, Germany
🇩🇪Boehringer Ingelheim Investigational Site 13, München, Germany
🇩🇪Boehringer Ingelheim Investigational Site 15, München, Germany
Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 103
- Registration Number
- NCT00535366
- Locations
- 🇧🇪
1249.1.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇧🇪1249.1.32001 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇳🇱1249.1.31003 Boehringer Ingelheim Investigational Site, Harderwijk, Netherlands
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
- Conditions
- HIV Infections
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 85
- Registration Number
- NCT00530920
- Locations
- 🇮🇹
1182.107.39001 Boehringer Ingelheim Investigational Site, Antella (fi), Italy
🇪🇸1182.107.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇪🇸1182.107.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain
Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 344
- Registration Number
- NCT00530842
- Locations
- 🇦🇹
205.334.4309 Boehringer Ingelheim Investigational Site, Gänserndorf, Austria
🇩🇪205.334.4904 Boehringer Ingelheim Investigational Site, Donaustauf, Germany
🇩🇪205.334.4901 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany
Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT00531206
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Wuppertal, Germany
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2080
- Registration Number
- NCT00528996
- Locations
- 🇺🇸
1205.14.042 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸1205.14.046 Boehringer Ingelheim Investigational Site, Riverside, California, United States
🇨🇦1205.14.145 Boehringer Ingelheim Investigational Site, Sherbrooke, Quebec, Canada
Dulcolax vs Placebo in Functional Constipation
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 368
- Registration Number
- NCT00526097
- Locations
- 🇬🇧
122.56.44011 Boehringer Ingelheim Investigational Site, Bedworth, United Kingdom
🇬🇧122.56.44032 Boehringer Ingelheim Investigational Site, Addlestone, United Kingdom
🇬🇧122.56.44018 Boehringer Ingelheim Investigational Site, Ash Vale, Aldershot, United Kingdom
Tiotropium In Exercise
- Conditions
- Pulmonary Disease, Chronic ObstructiveExercise
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 519
- Registration Number
- NCT00525512
- Locations
- 🇺🇦
205.368.38002 Boehringer Ingelheim Investigational Site, Kiev, Ukraine
🇺🇸205.368.01008 Boehringer Ingelheim Investigational Site, Fort Collins, Colorado, United States
🇺🇸205.368.01017 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States